Quest Diagnostics Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Vanguard Information Technology Index Fund ETF trades at $121.41. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while Vanguard Information Technology Index Fund ETF pays none. Which is the better fit depends on your goals.
| DGX | VGT | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | — |
52-Week High | $238.50 | $125.77 |
52-Week Low | $173.49 | $83.59 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Vanguard Information Technology ETF (VGT) trades at $121.60, up 1.12% with strong technical momentum as moving averages signal bullish sentiment. The ETF benefits from institutional accumulation and AI-driven technology sector strength, though RSI levels indicate potential near-term overbought conditions. Recent news highlights VGT's pure tech focus and outperformance versus broader tech ETFs.
VGT offers concentrated exposure to AI infrastructure leaders with strong institutional backing, but faces risks from sector concentration and valuation pressures. The ETF's momentum-driven returns depend on continued technology sector leadership, particularly in semiconductor and cloud computing segments where earnings growth remains robust.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →